Plant-Based Products Can Be Especially Effective for Anti-Aging
Dermatology Times
DECEMBER 16, 2024
Topical treatments with plant extracts improved skin hydration and elasticity while reducing melanin and erythema.
Mon.Dec 16, 2024
69 
Do you use men’s shaving creams and razors?
Beautiful With Brains - Skincare
DECEMBER 16, 2024
I have a confession to make. The first time I shaved, I stole my dad’s shaving cream and disposable (unused) razor. I didn’t see the point of buying my own when those were readily available for free. They did a pretty good job, so I kept using them, much to my dad’s puzzlement. He couldn’t […] The post Do you use men’s shaving creams and razors?
Navigating Psoriasis Treatment Across Patient Populations
Dermatology Times
DECEMBER 16, 2024
Michael Lewitt, MD, FAAD, highlighted the importance of personalized care, the decision-making process in psoriasis treatment, and the role ofpatient education.
Top 5 Non-Surgical Cosmetic Procedures Every Practitioner Should Know in 2024
AAAMS
DECEMBER 16, 2024
The world of aesthetic medicine is evolving rapidly, with non-surgical cosmetic procedures leading the way in popularity. Patients today seek treatments that offer impressive results with minimal downtime, making these procedures a must-know for practitioners aiming to stay ahead of the curve. If you’re looking to enhance your skills and meet growing patient demands, mastering these top non-surgical techniques is essential.
Facials for Acne: Must-Try Add-Ons for Clearer, Healthier Skin
Enlightened Beauty
DECEMBER 16, 2024
Hey beautiful! Ready to supercharge your acne treatment journey and attain the healthy skin you deserve? Let's talk about the magic of facial add-ons they're like your skin's secret power-ups, and honey, they're about to become your new best friend! Managing acne isn't just about tackling breakouts (though we'll definitely handle those!). It's more like creating a sacred ritual that nurtures your skin's health from the inside out, bringing it back into perfect harmony.
The Charming Jewel Box
Salon Today
DECEMBER 16, 2024
Nestled in Atlanta's upscale Chastain area, Salon O'Neil caters to discerning with stunning floors, floor-to-ceiling windows and Christian Lacroix Maison wallpaper. Take the tour of this 2024 Salon of Distinction.
Sign up to get articles personalized to your interests!
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
More Trending
Managing the White Space
Salon Today
DECEMBER 16, 2024
Increased openings in the schedule are a result of economic times, but your team members still can make these windows of time incredible productive. Managing white space was just one of the many effective time management salon leaders shared in one of our recent complimentary webinars you can watch on demand.
Skincare Solutions for Menopause: How to Address Common Skin Changes
US Dermatologt Partners
DECEMBER 16, 2024
As women enter menopause, they experience a variety of skin changes. Hormonal shifts, especially the drop in estrogen, lead to issues such as skin dryness, wrinkles, sagging, uneven tone, age spots, hair thinning, and even acne. While these changes are normal, many women want to maintain healthy, youthful-looking skin as they age. According to Dr. Alexandra Theriault of U.S.
Arcutis Submits sNDA for Roflumilast Cream 0.05% to FDA for Patients Ages 2 to 5 with Atopic Dermatitis
Dermatology Times
DECEMBER 16, 2024
The supplemental New Drug Application is supported by positive results from the INTEGUMENT-PED and INTEGUMENT-OLE trials.
Arcutis Submits Roflumilast Cream 0.05% (Zoryve) sNDA to the FDA for mild to moderate AD in children aged 2 to 5
The Dermatology Digest
DECEMBER 16, 2024
Arcutis Biotherapeutics, Inc. has submitted of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for roflumilast) cream 0.05% (Zoryve) for mild to moderate AD in children aged 2 to 5. When choosing a therapy for very young children living with AD, healthcare providers and caregivers have to account for unique considerations for pediatric patients, including sensitive skin, and select a medication that is appropriate for long-term use by a child with a chro
FDA Approves Tapinarof Cream, 1% for Atopic Dermatitis in Patients 2 Years and Older
Dermatology Times
DECEMBER 16, 2024
The approval is based on positive data stemming from the ADORING clinical trial program.
The Role of Informed Consent in Spa Treatments: Protecting Your Practice and ClientsÂ
Spa Industry Association
DECEMBER 16, 2024
Spa treatments are, by nature, hands on, so consent isnt perhaps something that youd think of as it seems implied. However, theres far more to it than many people realize. Informed consent is an essential aspect of ethical practice in the spa industry and it forms the backbone of legal compliance in spa operations. Want to ensure you always protect your spas practice and clients?
Choosing Effective Laser Devices for Improving Skin Tone and Texture
Dermatology Times
DECEMBER 16, 2024
A panelist discusses how selecting the optimal laser device requires careful consideration of wavelength, pulse duration, and spot size to effectively target specific skin concerns while minimizing potential adverse effects.
Patient Enrollment Is Open for Phase 3 Study Evaluating HyBryte in CTCL
The Dermatology Digest
DECEMBER 16, 2024
Patient enrollment is open for a confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL). HyBryte is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by safe, visible light approximately 24 hours later.
The Burden of Prurigo Nodularis
Dermatology Times
DECEMBER 16, 2024
Increased awareness for prurigo nodularis may help to usher in a new era of timelier and more targeted treatment.
ICYMI: FDA Approves Galderma's Nemolizumab for Moderate to Severe Atopic Dermatitis in Patients 12 and Older
Dermatology Times
DECEMBER 16, 2024
Nemolizumab is intended for use in combination with topical corticosteroids and/or calcineurin inhibitors in this indication.
2024 Key Insights: Skin Cancer
Dermatology Times
DECEMBER 16, 2024
Join Dermatology Times quarterly editor in chief Aaron Farberg, MD, as he highlights significant advancements in gene expression profile testing for cutaneous melanoma.
Demographics and Baseline Characteristics Across Spesolimab Dose Groups
Dermatology Times
DECEMBER 16, 2024
Panelists discuss how the Effisayil 2 trial included diverse patient demographics across different spesolimab dose groups, with baseline characteristics such as age, disease severity, and history of GPP flares influencing the treatment outcomes and safety data.
Considerations for Surgical vs Nonsurgical Approaches for BCC
Dermatology Times
DECEMBER 16, 2024
Panelists discuss how factors such as tumor size, location, patient age, and overall health guide the decision between surgical excision and nonsurgical treatments such as topical therapies or radiation for managing basal cell carcinoma (BCC) effectively.
Spesolimab Efficacy Data
Dermatology Times
DECEMBER 16, 2024
Panelists discuss how the efficacy data from the Effisayil 2 trial demonstrate that spesolimab significantly delayed the time to first GPP flare and reduced flare severity, highlighting its potential as an effective treatment for preventing life-threatening flares in GPP patients.
Talking to Patients About Itch Management
Dermatology Times
DECEMBER 16, 2024
Melodie Young, MSN, A/GNP-C, discusses how to effectively communicate with patients about managing itch in prurigo nodularis, offering practical tips such as setting realistic expectations, emphasizing the importance of consistent skin care routines, and exploring both pharmacologic and non-pharmacologic strategies to alleviate discomfort.
Provider and Patient Considerations for Prurigo Nodularis Treatment
Dermatology Times
DECEMBER 16, 2024
Melodie Young, MSN, A/GNP-C, discusses how clinical and practical considerations, such as disease severity, patient preferences, and comorbidities, should guide the selection of treatment for prurigo nodularis, and emphasizes the importance of educating patients about the role of systemic therapies, addressing their concerns, and improving awareness of available treatment options.
POLL: Is Your Practice Closed for the Holidays?
Dermatology Times
DECEMBER 16, 2024
Click here to answer today's poll and read more about practice management around the holiday season.
New Systemic Treatments for Prurigo Nodularis
Dermatology Times
DECEMBER 16, 2024
Melodie Young, MSN, A/GNP-C, discusses how the FDA-approved systemic treatments for prurigo nodularis, dupilumab and nevolizumabnemolizumab, differ in their mechanisms of actiondupilumab targeting IL-4 and IL-13, and nevolizumabnemolizumab targeting IL-31and highlights their similar efficacy in reducing pruritus and lesion size, while also considering differences in safety profiles and treatment considerations.
Let's personalize your content